Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy.

IMRT MR-guided adaptive radiotherapy Prostate SBRT VMAT

Journal

Technical innovations & patient support in radiation oncology
ISSN: 2405-6324
Titre abrégé: Tech Innov Patient Support Radiat Oncol
Pays: England
ID NLM: 101762366

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 29 11 2021
revised: 13 01 2022
accepted: 09 02 2022
entrez: 7 3 2022
pubmed: 8 3 2022
medline: 8 3 2022
Statut: epublish

Résumé

To compare the dosimetry of prostate stereotactic radiotherapy (SBRT) delivered by adaptive intensity modulated radiotherapy (A-IMRT) and 3 degree of freedom volumetric modulated arc therapy (3DOF-VMAT). Twenty-five prostate patients treated with High Dose Rate (HDR) brachytherapy followed by SBRT were included (fifteen with hydrogel spacer in place for treatment). Interfraction changes in the volume of prostate, rectum and bladder were measured. Fractional dose to these structures was estimated for A-IMRT and 3DOF-VMAT for comparison against the corresponding reference dose and between each other. Clinically acceptable dose was delivered to prostate in all 125 fractions through A-IMRT and 3DOF-VMAT. A-IMRT was better than 3DOF-VMAT in reducing dose to 1 cm Despite the presence of large interfraction organ volumes changes, clinically acceptable dose was delivered to the prostate by both systems. A-IMRT facilitated a greater rectal sparing from the high dose region than 3DOF-VMAT. Further reduction in rectal dose could be achieved by hydrogel spacer to displace the rectum, or by adaptation delivered by VMAT.

Identifiants

pubmed: 35252598
doi: 10.1016/j.tipsro.2022.02.003
pii: S2405-6324(22)00007-5
pmc: PMC8892164
doi:

Types de publication

Journal Article

Langues

eng

Pagination

64-70

Informations de copyright

© 2022 University Health Network.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Phys Imaging Radiat Oncol. 2020 Dec 24;17:20-24
pubmed: 33898773
Semin Radiat Oncol. 2019 Jul;29(3):245-257
pubmed: 31027642
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1026-33
pubmed: 25832693
Med Phys. 2008 Jan;35(1):310-7
pubmed: 18293586
Cancers (Basel). 2021 Apr 09;13(8):
pubmed: 33918650
Radiat Oncol. 2021 Jul 21;16(1):133
pubmed: 34289868
Br J Radiol. 2021 Jan 1;94(1117):20200848
pubmed: 33095659
Radiat Oncol. 2020 Aug 21;15(1):203
pubmed: 32825848
Phys Med Biol. 2005 Aug 7;50(15):3589-97
pubmed: 16030384
Clin Transl Radiat Oncol. 2019 Apr 08;18:98-101
pubmed: 31341983
Brachytherapy. 2018 Jan - Feb;17(1):59-67
pubmed: 28764881
Radiat Oncol. 2015 Oct 24;10:215
pubmed: 26499473
Technol Cancer Res Treat. 2017 Apr;16(2):178-187
pubmed: 27199276
J Appl Clin Med Phys. 2021 Sep;22(9):49-58
pubmed: 34342134
Clin Transl Radiat Oncol. 2020 Apr 29;23:35-42
pubmed: 32395640
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):996-1001
pubmed: 18455326
Tumori. 2017 Sep 18;103(5):395-404
pubmed: 28885678
Radiother Oncol. 2016 Apr;119(1):150-3
pubmed: 26861739
Br J Radiol. 2020 Apr;93(1108):20190789
pubmed: 31971829
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1169-78
pubmed: 22704703
Brachytherapy. 2016 Mar-Apr;15(2):147-55
pubmed: 26832674
Radiat Oncol. 2014 Jan 13;9:22
pubmed: 24410739
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):361-373
pubmed: 29353654
Pract Radiat Oncol. 2011 Oct-Dec;1(4):243-50
pubmed: 24674002
Phys Imaging Radiat Oncol. 2019 Apr 24;10:19-24
pubmed: 33458263
J Appl Clin Med Phys. 2004 Spring;5(2):29-41
pubmed: 15738911
Strahlenther Onkol. 2019 Jun;195(6):517-525
pubmed: 30443682
Clin Transl Radiat Oncol. 2019 Apr 01;18:68-73
pubmed: 31341979
Br J Radiol. 2014 Dec;87(1044):20140459
pubmed: 25354015
Strahlenther Onkol. 2005 Jul;181(7):424-30
pubmed: 15995835
Strahlenther Onkol. 2021 Feb;197(2):89-96
pubmed: 33301049
Phys Imaging Radiat Oncol. 2018 Jul 21;7:1-8
pubmed: 33458398
Clin Transl Radiat Oncol. 2019 Apr 02;18:54-59
pubmed: 31341976
Radiother Oncol. 2021 Jun;159:146-154
pubmed: 33775715
Phys Med Biol. 2017 Nov 14;62(23):L41-L50
pubmed: 29135471

Auteurs

Vickie C Kong (VC)

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Jennifer Dang (J)

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.

Winnie Li (W)

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Inmaculada Navarro (I)

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Jerusha Padayachee (J)

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Victor Malkov (V)

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Jeff Winter (J)

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Srinivas Raman (S)

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Alejandro Berlin (A)

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Charles Catton (C)

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Padraig Warde (P)

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Peter Chung (P)

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Classifications MeSH